---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010286"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T13:32:53.876164+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion reports FY2022 net loss of $81.8M; cash $113.4M; clinical progress across three trials

## Summary
- Net loss $25.3M in Q4 2022 ($14.7M in Q4 2021); full-year loss $81.8M vs $41.6M in 2021.
- Cash, equivalents, and investments $113.4M at Dec 31, 2022, down from $175.7M a year earlier.
- R&D expense $62.7M in FY2022 vs $28.0M; increase driven by clinical/preclinical development of BMF-219 and BMF-500.
- BMF-219 advanced in three trials: COVALENT-101 (liquid tumors), COVALENT-102 (KRAS-mutant solid tumors), COVALENT-111 (type 2 diabetes); initial diabetes data reported March 2023.
- IND for BMF-500 (FLT3 inhibitor) on track for H1 2023; third development candidate from FUSION platform expected H1 2023.

## SEC filing metadata
- accession: 0000950170-23-010286
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000095017023010286/0000950170-23-010286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000095017023010286/bmea-20230328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010286
- JSON: https://secwatch.observer/filing/0000950170-23-010286.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010286.txt

## Key facts
- Earnings Releases
  Biomea Fusion, Inc. reported financial results for the quarter ended and year ended December 31, 2022.
  - Period: the quarter ended and year ended December 31, 2022
  - Result: reported results
  source text: On March 28, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840439/000095017023010286/0000950170-23-010286-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.